JP2016153436A - 微生物感染の治療に使用するためのタマリンド種子多糖 - Google Patents
微生物感染の治療に使用するためのタマリンド種子多糖 Download PDFInfo
- Publication number
- JP2016153436A JP2016153436A JP2016110020A JP2016110020A JP2016153436A JP 2016153436 A JP2016153436 A JP 2016153436A JP 2016110020 A JP2016110020 A JP 2016110020A JP 2016110020 A JP2016110020 A JP 2016110020A JP 2016153436 A JP2016153436 A JP 2016153436A
- Authority
- JP
- Japan
- Prior art keywords
- tamarind seed
- seed polysaccharide
- tsp
- treatment
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000004298 Tamarindus indica Nutrition 0.000 title claims abstract description 27
- 150000004676 glycans Chemical class 0.000 title claims abstract description 27
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 27
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 27
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 230000000813 microbial effect Effects 0.000 title claims abstract description 11
- 240000004584 Tamarindus indica Species 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 241000596504 Tamarindus Species 0.000 claims abstract description 25
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 239000004599 antimicrobial Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 238000011200 topical administration Methods 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 20
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 12
- 201000010927 Mucositis Diseases 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 7
- 208000003265 stomatitis Diseases 0.000 claims description 7
- 244000133098 Echinacea angustifolia Species 0.000 claims description 5
- 235000018625 Helichrysum angustifolium Nutrition 0.000 claims description 5
- 244000292571 Helichrysum italicum Species 0.000 claims description 5
- 235000013530 Helichrysum italicum Nutrition 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000014134 echinacea Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000003357 wound healing promoting agent Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 229940034610 toothpaste Drugs 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 244000005700 microbiome Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000157282 Aesculus Species 0.000 description 2
- 102100038326 Beta-defensin 4A Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- NSEWTSAADLNHNH-TXZJYACMSA-N Proanthocyanidin A-2 Natural products C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-TXZJYACMSA-N 0.000 description 2
- 229920002982 Procyanidin A2 Polymers 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- -1 gums Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 241000157280 Aesculus hippocastanum Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 101710125298 Beta-defensin 2 Proteins 0.000 description 1
- 101710176951 Beta-defensin 4A Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229940041667 oral paste Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229940032067 peg-20 stearate Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940044959 vaginal cream Drugs 0.000 description 1
- 239000000522 vaginal cream Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
Abstract
【解決手段】本発明は、タマリンド種子多糖(TSP)の抗微生物物質としての使用およびそれを有効成分として含有する抗微生物性組成物に関する。TSPを含有する抗微生物性組成物は、皮膚および粘膜の微生物感染の治療および/または予防における局所投与のために特に有用である。
【選択図】なし
Description
本発明は、タマリンド種子多糖(polysaccharide)の抗微生物物質(antimicrobial)としての使用およびそれを有効成分として含有する抗微生物性組成物(antimicrobial composition)に関する。
タマリンド種子多糖(TSP)は、高さ15メートルにも達することがあり、鞘状の果実をつける常緑植物であるタマリンダス・インディカ(Tamarindus indica)の種子から得られる天然の多糖高分子である。インド、アフリカ、および極東の全域にわたってよく見られ、主に食物として栽培されている。果実は、高い割合で多糖を有する大きい種子を含有しており、この種子は、生命のエネルギー源となる物質を蓄積および保存する機能を備えている。タマリンド種子は、元々、廃棄物とみなされていたが、その後、粉砕して澱粉質の製品(タマリンドガムまたはタマリンド穀粒粉末(tamarind nut powder)として知られる)を得た後、種々の用途が見出された。これらの用途で最も重要なものは、タマリンドガムをサイズ剤および粘着剤として使用する繊維産業および紙産業におけるものである。また食品産業においては、他の多糖と同様に、タマリンドガムを、種々の製品における増粘剤、ゲル化剤、安定化剤、および結合剤として使用する。未加工のタマリンドガムは、商業的に入手可能な製品であり、この製品は、65〜73重量%の多糖、15〜23重量%のタンパク質、3〜8重量%の脂肪および油、ならびに2〜4重量%の灰分を、少量の原繊維、タンニンおよび他の不純物とともに含有する。
本発明は、微生物感染の予防および/または治療におけるタマリンド種子多糖の使用に関する。
本発明者らは、タマリンド種子多糖(以下、TSPと称する)が、特に局所的に投与されるときに、抗微生物特性を有することを見出した。
例1−局所使用のためのクリーム
TSP(タマリンド種子多糖) 0.200%(w/w)
アエスクルス・ヒッポカスタヌム(Aesculus hippocastanum)
抽出物 0.200%(w/w)
ヘリクリスム・イタリクム(Helichrysum italicum)抽出物
0.200%(w/w)
水 75.150%(w/w)
モンタノブ(Montanov)202 5.000%(w/w)
ラノール(Lanol)99 10.000%(w/w)
セピリフト(Sepilift)DPHP 1.000%(w/w)
モノイバター(Monoi Butter) 2.000%(w/w)
セピフィール(Sepifeel)ワン 1.000%(w/w)
アクアキシル(Aquaxyl) 3.000%(w/w)
パンテノール 1.000%(w/w)
トコフェリル酢酸 0.600%(w/w)
セピサイド(Sepicide)HB 0.300%(w/w)
香料 0.250%(w/w)
水酸化ナトリウム(30%溶液) 0.100%(w/w)
合計 100.000%(w/w)
例2−経口ペースト
TSP(タマリンド種子多糖) 0.300%(w/w)
アエスクルス・ヒッポカスタヌム抽出物 0.200%(w/w)
ザントキシルム・ブンゲアヌム抽出物 0.100%(w/w)
ソルビトール 50.000%(w/w)
蒸留水 35.040%(w/w)
ケイ酸 8.000%(w/w)
カルボキシメチルセルロース 5.000%(w/w)
ソルビン酸カリウム 0.300%(w/w)
安息香酸ナトリウム 0.300%(w/w)
PEG−40水添ヒマシ油 0.160%(w/w)
サッカリンナトリウム 0.100%(w/w)
香味料 0.500%(w/w)
合計 100.000%(w/w)
例3−膣クリーム
TSP(タマリンド種子多糖) 0.200%(w/w)
アエスクルス・ヒッポカスタヌム抽出物 0.200%(w/w)
蒸留水 73.300%(w/w)
流動パラフィン 15.000%(w/w)
セテアリルアルコール−PEG−20ステアリン酸塩
9.000%(w/w)
ジメチコン 1.000%(w/w)
フェノキシエタノール 0.500%(w/w)
イミダゾリジニル尿素 0.300%(w/w)
プロピルパラベン 0.150%(w/w)
メチルパラベン 0.150%(w/w)
EDTAナトリウム 0.100%(w/w)
乳酸 0.100%(w/w)
合計 100.000%(w/w)
例4−NHEKにおけるβデフェンシン発現
ヒトケラチノサイトを、10%FBS(ウシ胎児血清)および10ml/Lペニシリン/ストレプトマイシンを含むダルベッコ変法イーグル培地で培養した。NHEK(正常ヒト表皮ケラチノサイト)初代ヒトケラチノサイトを、KGM(ケラチノサイト増殖培地)中で、無血清環境において培養した。細胞を、培地のみ(陰性標準)で、または大腸菌(5mcg/ml)由来のLPS(リポ多糖、陽性標準)を添加した培地で、培養した。
Claims (14)
- 微生物感染の予防および/または治療に使用するためのタマリンド種子多糖。
- 感染が、細菌、酵母、ウイルスまたは真菌によって引き起こされる、請求項1に記載のタマリンド種子多糖。
- 感染が、細菌感染である、請求項2に記載のタマリンド種子多糖。
- 皮膚または粘膜の微生物感染の予防および/または治療に使用するための、請求項1〜3に記載のタマリンド種子多糖。
- 局所投与のための、請求項1〜4に記載のタマリンド種子多糖。
- 粘膜炎および口内炎の治療に使用するための、請求項1〜5に記載のタマリンド種子多糖。
- 1種または複数の許容される賦形剤と混合されている有効成分としてのタマリンド種子多糖を含有する、抗微生物医薬および/または皮膚化粧用組成物。
- 局所投与のための、請求項7に記載の組成物。
- クリーム、軟膏、ゲル、ガム、練り歯磨き、洗口剤またはシャンプーの形態である、請求項7または8に記載の組成物。
- 抗微生物剤、抗炎症剤、および創傷治癒剤からなる群から選択される少なくとも1種のさらなる有効成分を含む、請求項7〜9に記載の組成物。
- ヘリクリスム・イタリクム、エキナセア属種、アエスクルス・ヒッポカスタヌム、ザントキシルム・ブンゲアヌムまたはその混合物の抽出物をさらに含む、請求項7〜10に記載の組成物。
- タマリンド種子多糖量が0.1〜5重量%の範囲である、請求項7〜11に記載の組成物。
- 微生物感染の予防用薬剤および/または治療用薬剤の製造のためのタマリンド種子多糖の使用。
- 治療的有効量のタマリンド種子多糖を投与するステップを含む、微生物感染を有する患者の予防方法および/または治療方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20100933 | 2010-05-24 | ||
ITMI2010A000933 | 2010-05-24 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013511628A Division JP2013526594A (ja) | 2010-05-24 | 2011-05-23 | 微生物感染の治療に使用するためのタマリンド種子多糖 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016153436A true JP2016153436A (ja) | 2016-08-25 |
JP6239041B2 JP6239041B2 (ja) | 2017-11-29 |
Family
ID=43477979
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013511628A Pending JP2013526594A (ja) | 2010-05-24 | 2011-05-23 | 微生物感染の治療に使用するためのタマリンド種子多糖 |
JP2016110020A Active JP6239041B2 (ja) | 2010-05-24 | 2016-06-01 | 微生物感染の治療に使用するためのタマリンド種子多糖 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013511628A Pending JP2013526594A (ja) | 2010-05-24 | 2011-05-23 | 微生物感染の治療に使用するためのタマリンド種子多糖 |
Country Status (21)
Country | Link |
---|---|
US (1) | US10206943B2 (ja) |
EP (1) | EP2575971B1 (ja) |
JP (2) | JP2013526594A (ja) |
KR (1) | KR101878450B1 (ja) |
CN (1) | CN103025386B (ja) |
AU (1) | AU2011257387B2 (ja) |
BR (1) | BR112012029739A2 (ja) |
CA (1) | CA2800382C (ja) |
CL (1) | CL2012003266A1 (ja) |
DK (1) | DK2575971T3 (ja) |
ES (1) | ES2560953T3 (ja) |
HK (1) | HK1183454A1 (ja) |
HU (1) | HUE026862T2 (ja) |
IL (1) | IL223176A (ja) |
MX (1) | MX341220B (ja) |
PL (1) | PL2575971T3 (ja) |
PT (1) | PT2575971E (ja) |
RU (1) | RU2571063C2 (ja) |
SG (1) | SG185693A1 (ja) |
SI (1) | SI2575971T1 (ja) |
WO (1) | WO2011147767A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20121917A1 (it) * | 2012-11-09 | 2014-05-10 | Velleja Res Srl | Composizioni per uso vaginale comprendenti polisaccaridi da tamarindo |
WO2015158771A1 (en) | 2014-04-15 | 2015-10-22 | Novintethical Pharma Sa | Compositions based on xyloglucan and proteins for the treatment of intestinal disorders |
CN104844809B (zh) * | 2015-03-25 | 2017-12-08 | 北京林业大学 | 一种罗望子多糖凝胶的制备方法 |
ES2705692T3 (es) | 2015-06-11 | 2019-03-26 | Novintethical Pharma Sa | Composiciones nasales tópicas que contienen xiloglucanos para usar como descongestionantes |
WO2017173240A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
WO2017173241A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
DE102016207337A1 (de) | 2016-04-29 | 2017-11-02 | Henkel Ag & Co. Kgaa | Zahncreme zur Verbesserung der Zahnfleischadhäsion |
WO2018098152A1 (en) | 2016-11-23 | 2018-05-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
RU2754067C2 (ru) * | 2018-05-18 | 2021-08-25 | Общество с ограниченной ответственностью "НИАРМЕДИК ФАРМА" | Противомикробная композиция на основе полифенолов и полисахаридов, способ ее получения и применение |
JP7138496B2 (ja) * | 2018-07-06 | 2022-09-16 | 花王株式会社 | 抗菌ペプチド発現促進剤 |
TR202100436A2 (tr) * | 2021-01-12 | 2021-01-21 | Almediko Saglik Ueruenleri Turizm Gida Sanayi Ve Ticaret Ltd Sirketi | Üst solunum yollari vi̇ral enfeksi̇yonlarinda kullanilan anti̇-vi̇ral ajan ve bunu i̇çeren farmasöti̇k kompozi̇syonu |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09136816A (ja) * | 1995-11-14 | 1997-05-27 | Dainippon Pharmaceut Co Ltd | 養毛料 |
US5876729A (en) * | 1995-01-03 | 1999-03-02 | Laboratoires Serobiologiques (Sa) | Use of extracts of tamarind seeds rich in xyloglycans and cosmetic or pharmaceutical product containing such extracts |
JP2004067660A (ja) * | 2002-08-02 | 2004-03-04 | Coletica | 2型又は3型ヒトβ−デフェンシンを刺激する活性成分とその活性成分を含有する化粧用組成物及び医薬組成物 |
JP2005162663A (ja) * | 2003-12-02 | 2005-06-23 | Asahi Denka Kogyo Kk | 皮膚用基剤 |
JP2008201789A (ja) * | 2001-08-10 | 2008-09-04 | Toray Ind Inc | 多糖類含有組成物およびその用途 |
WO2009040847A2 (en) * | 2007-08-13 | 2009-04-02 | N.B.S. S.R.L. | Dermocosmetic compositions based on tamarind seed polysaccharide and vegetable extracts |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3340877B2 (ja) * | 1995-02-24 | 2002-11-05 | 丸善製薬株式会社 | ヒアルロニダーゼ阻害剤および化粧料 |
IT1283911B1 (it) * | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US6162393A (en) * | 1998-08-06 | 2000-12-19 | Ndt, Inc. | Contact lens and ophthalmic solutions |
WO2000057888A1 (fr) * | 1999-03-26 | 2000-10-05 | Sunstar Inc. | Compositions destinees a la prevention et au traitement de l'allergie de type i |
FR2851469B1 (fr) * | 2003-01-14 | 2007-09-21 | Jean Noel Thorel | Composition et procede de soin contenant un inhibiteur de glucosidase |
BRPI0414868A (pt) * | 2003-10-03 | 2006-11-28 | Allergan Inc | composições e métodos compreendendo compostos relacionados com prostaglandina e peptìdios da famìlia do fator trifoliado para o tratamento de glaucoma com hiperemia reduzida |
DE10394357T5 (de) * | 2003-12-30 | 2007-03-08 | Council Of Scientific & Industrial Research | Oro-dentale-Kräuterpflegezusammensetzung und Verfahren zur Herstellung derselben |
ATE470453T1 (de) * | 2004-04-06 | 2010-06-15 | Novimmune Sa | Verfahren zur behandlung von atherosklerose |
US20060263306A1 (en) * | 2005-05-19 | 2006-11-23 | Pauline Pan | Compositions having improved substantivity |
JP2006325447A (ja) * | 2005-05-24 | 2006-12-07 | Nisshin Pharma Inc | 抗ヘリコバクター・ピロリ飲食品 |
ITBO20050388A1 (it) | 2005-06-06 | 2006-12-07 | Alfa Wassermann Spa | Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche |
JP5134778B2 (ja) * | 2006-03-10 | 2013-01-30 | 日清オイリオグループ株式会社 | ゲル組成物及び該ゲル組成物を使用したパック化粧料 |
ITRM20070510A1 (it) * | 2007-10-02 | 2009-04-03 | Rmfa Trading S A | Composizioni oftalmiche a base di polisaccaride del seme di tamarindo e acido ialuronico. |
-
2011
- 2011-05-23 KR KR1020127030677A patent/KR101878450B1/ko active IP Right Grant
- 2011-05-23 AU AU2011257387A patent/AU2011257387B2/en active Active
- 2011-05-23 BR BR112012029739A patent/BR112012029739A2/pt not_active Application Discontinuation
- 2011-05-23 ES ES11724579.5T patent/ES2560953T3/es active Active
- 2011-05-23 WO PCT/EP2011/058332 patent/WO2011147767A1/en active Application Filing
- 2011-05-23 US US13/699,406 patent/US10206943B2/en active Active
- 2011-05-23 JP JP2013511628A patent/JP2013526594A/ja active Pending
- 2011-05-23 PL PL11724579T patent/PL2575971T3/pl unknown
- 2011-05-23 DK DK11724579.5T patent/DK2575971T3/en active
- 2011-05-23 HU HUE11724579A patent/HUE026862T2/en unknown
- 2011-05-23 SG SG2012085791A patent/SG185693A1/en unknown
- 2011-05-23 EP EP11724579.5A patent/EP2575971B1/en active Active
- 2011-05-23 CN CN201180025355.0A patent/CN103025386B/zh active Active
- 2011-05-23 MX MX2012013606A patent/MX341220B/es active IP Right Grant
- 2011-05-23 CA CA2800382A patent/CA2800382C/en active Active
- 2011-05-23 PT PT117245795T patent/PT2575971E/pt unknown
- 2011-05-23 SI SI201130725T patent/SI2575971T1/sl unknown
- 2011-05-23 RU RU2012149863/15A patent/RU2571063C2/ru active
-
2012
- 2012-11-22 CL CL2012003266A patent/CL2012003266A1/es unknown
- 2012-11-22 IL IL223176A patent/IL223176A/en active IP Right Grant
-
2013
- 2013-09-25 HK HK13110943.2A patent/HK1183454A1/zh unknown
-
2016
- 2016-06-01 JP JP2016110020A patent/JP6239041B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876729A (en) * | 1995-01-03 | 1999-03-02 | Laboratoires Serobiologiques (Sa) | Use of extracts of tamarind seeds rich in xyloglycans and cosmetic or pharmaceutical product containing such extracts |
JPH09136816A (ja) * | 1995-11-14 | 1997-05-27 | Dainippon Pharmaceut Co Ltd | 養毛料 |
JP2008201789A (ja) * | 2001-08-10 | 2008-09-04 | Toray Ind Inc | 多糖類含有組成物およびその用途 |
JP2004067660A (ja) * | 2002-08-02 | 2004-03-04 | Coletica | 2型又は3型ヒトβ−デフェンシンを刺激する活性成分とその活性成分を含有する化粧用組成物及び医薬組成物 |
JP2005162663A (ja) * | 2003-12-02 | 2005-06-23 | Asahi Denka Kogyo Kk | 皮膚用基剤 |
WO2009040847A2 (en) * | 2007-08-13 | 2009-04-02 | N.B.S. S.R.L. | Dermocosmetic compositions based on tamarind seed polysaccharide and vegetable extracts |
Non-Patent Citations (3)
Title |
---|
CHEMOTHERAPY, vol. 43, JPN6017005493, 1997, pages 211 - 217, ISSN: 0003586905 * |
J. ANTIMICROB. CHEMOTHER., vol. 39, no. 3, JPN6017005492, 1997, pages 339 - 345, ISSN: 0003586904 * |
日歯保存誌, vol. 51, no. 1, JPN6017005494, 2008, pages 16 - 23, ISSN: 0003586906 * |
Also Published As
Publication number | Publication date |
---|---|
SG185693A1 (en) | 2012-12-28 |
MX2012013606A (es) | 2012-12-17 |
WO2011147767A1 (en) | 2011-12-01 |
HUE026862T2 (en) | 2016-07-28 |
IL223176A0 (en) | 2013-02-03 |
DK2575971T3 (en) | 2016-02-29 |
KR101878450B1 (ko) | 2018-07-13 |
PL2575971T3 (pl) | 2016-06-30 |
IL223176A (en) | 2017-08-31 |
CL2012003266A1 (es) | 2013-03-22 |
US10206943B2 (en) | 2019-02-19 |
KR20130108979A (ko) | 2013-10-07 |
CA2800382C (en) | 2019-09-17 |
CN103025386B (zh) | 2015-12-16 |
AU2011257387A1 (en) | 2012-12-13 |
EP2575971A1 (en) | 2013-04-10 |
PT2575971E (pt) | 2016-03-04 |
SI2575971T1 (sl) | 2016-02-29 |
ES2560953T3 (es) | 2016-02-23 |
CA2800382A1 (en) | 2011-12-01 |
CN103025386A (zh) | 2013-04-03 |
HK1183454A1 (zh) | 2013-12-27 |
EP2575971B1 (en) | 2015-12-16 |
BR112012029739A2 (pt) | 2016-08-09 |
MX341220B (es) | 2016-08-10 |
RU2012149863A (ru) | 2014-06-27 |
JP2013526594A (ja) | 2013-06-24 |
JP6239041B2 (ja) | 2017-11-29 |
AU2011257387B2 (en) | 2016-10-13 |
RU2571063C2 (ru) | 2015-12-20 |
US20130149257A1 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6239041B2 (ja) | 微生物感染の治療に使用するためのタマリンド種子多糖 | |
US20060105000A1 (en) | Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil | |
JP5981419B2 (ja) | 炎症性疾患の治療に使用するためのタマリンド種子多糖 | |
US20200297780A1 (en) | Anti-inflammatory compositions, methods and uses thereof | |
WO2020252411A1 (en) | Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue | |
NO328979B1 (no) | Anvendelse av diklorbenzylalkohol for fremstilling av et preparat for topisk behandling av inflammasjon | |
RU2749713C1 (ru) | Стоматологический гель | |
RU2749710C1 (ru) | Стоматологическое средство в виде фитопленки | |
KR20220026241A (ko) | 사용성 및 위생성이 향상된 롤 타입 연고 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160601 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170915 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171031 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6239041 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |